Contracts that restrict patent filing or impose patent-licensing obligations This briefing note illustrates examples of contractual language from data-sharing agreements and material transfer agreements that limit patent filing or impose specific licensing terms. KEI Briefing Note 2025:4 Arianna Schouten December… Continue Reading
The USPTO has a request for comment on the need for a statutory experimental use exception for patents. (89 FR 53963). The USPTO uploads the comments to Regulations.Gov, docket PTO-C-2024-0023. KEI filed comments on September 10, 2024: KEI-Experimental-use-exception-10Sept2024 September 10,… Continue Reading
Today the government of Bolivia and Biolyse, a company based in Canada, signed an agreement to acquire COVID-19 vaccines manufactured by the company, if Canada grants them a compulsory license. Biolyse is a manufacturer of cancer drugs with the potential… Continue Reading
A German patent court has ordered a compulsory license under Section 24 of the Patent Act, allowing Merck (US) to continue to market the HIV drug raltegravir (marketed as Isentress).
GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here. Continue Reading
The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these: